Searched for
SYNTHETIC PEPTIDES
In the 1860s, an inventor chased an ivory substitute and helped push celluloid into historyIn the 1860s, a billiard ball competition ignited a quest for substitutes for ivory. John Wesley Hyatt's groundbreaking research culminated...- Holding stocks is harder than finding them: 10 mid- and small-caps stocks that may be worth holding on toHolding a stock is not an act of blind faith. It is not refusing to change one’s mind. It is not averaging down because the stock has falle...
- These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 25%, according to analystsWhat we are witnessing in the market these days is similar to scenarios that have played out in the past. There have been many points in th...
- Sun Pharma deal: Perception changer for Indian pharma sector? 10 pharma stocks with upside potential of up to 38%The Indian pharma sector made its initial global forays almost a quarter century ago. Companies sought out markets abroad, learnt to deal w...
- Biocon launches diabetes, obesity management drug in UKBiocon has launched Liraglutide, a drug for diabetes and obesity management, in the UK under the brand names Liraglutide Biocon and Biolide...
- Suven Pharma sets sights on M&As to scale up tech expertise & order bookSuven Pharmaceuticals, backed by Advent International, is eyeing further mergers and acquisitions to bolster its capabilities and order boo...
- Stock to watch: Shilpa Medicare stock in focus after receiving CEP from EDQM for diabetes drugShares of Shilpa Medicare will be highlighted as its subsidiary, Shilpa Pharma Lifesciences, obtained a certificate of suitability from Eur...
- Biocon inks licensing, supply pact with South Korea's Handok for chronic weight management productBiocon signs exclusive licensing agreement with Handok for commercialisation of synthetic Liraglutide in South Korea, expanding portfolio t...
- Cipla Q2 Results: Net profit jumps 45% YoY to Rs 1131 croreCipla's India business that contributes 42% to overall revenue grew 10% YoY to Rs 2817 crore in Q2FY24 with continued momentum across brand...
- For risk takers; 4 smallcaps with right mix of ROE and ROCE and having an upside scope of up to 26%While small caps have been moving upward for the last many weeks, as the nifty touches a new high every second day, higher participation of...
- Enzene Biosciences raises $50 million to expand ops in India, US marketsIn a press statement, Enzene said it would leverage the fresh funds to enhance its manufacturing capabilities and drive expansion in its co...
- How technology can decrease carbon footprint in agricultureAgriculture accounts for close to 80% of total nitrous oxide emissions, mainly generated from the application of synthetic nitrogen fertili...
- Piramal Pharma to buy API maker Hemmo PharmaPiramal Pharma Solutions (PPS), the Contract Development and Manufacturing Organization (CDMO) of Piramal Pharma Limited, will acquire API ...
- Synthetic peptide can repair cognitive decline, help treat Alzheimer's earlyThese peptides can block amyloid beta aggregation at the early and most toxic stage when oligomers form.
- Simple blood test could detect arthritis 16 years in advanceThe blood test looks for antibodies that recognise the protein tenascin-C and could reliably identify those who will contract rheumatoid ar...
- New compound may help treat type-2 diabetesThe new technique may enable researchers to quickly find drug candidates that activate cellular receptors in desired ways.
- Aurobindo Pharma targets a revenue of over $3 billion by 2017-18Aurobindo Pharma is targeting a revenue of over $3 billion (over Rs 19,800 crore) by 2017-18 and plans to expand its basket with drugs to t...
- Aurobindo Pharma to expand product basket; eyes $3 billion revenues by FY18Aurobindo is targetting a revenue of over $ 3 billion by 2017-18 and plans to expand its basket with new drugs to treat cancer.
- New drug effective against antibiotic-resistant 'superbugs'On the tail end of HIV surface protein, there is a sequence of amino acids that the virus uses to "punch into" and infect cells.
- Dr Reddy's relocates Chirotech Tech Centre to Cambridge in UKIndia's leading pharmaceutical firm Dr Reddy's Laboratories has moved its UK subsidiary,Chirotech, to a new purpose built lab facility at t...
Load More
